Phaseline

Targets › F11

F11 (Coagulation factor XI): drug programs, companies and trials

6 programs from 5 companies in 23 trials: 14 Phase 3, 5 Phase 1, 4 Phase 2; Cardiovascular, Genitourinary, Other; next expected readout Dec 2026.

Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. (UniProt, P03951)

Open in Phaseline: the race on F11, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Johnson & Johnson (Janssen)Milvexian
Coagulation factor XI inhibitor
F11Phase 3Ischemic Stroke; Ischemic Attack, Transient; Atrial FibrillationDec 2026
Regeneron PharmaceuticalsREGN7508
Factor XI inhibitor
F11Phase 3Venous Thromboembolism (VTE); Symptomatic Venous Thromboembolism (VTE); Atrial Fibrillation (AF); Peripheral Artery Disease (PAD) …Feb 2027
Regeneron PharmaceuticalsREGN9933
Factor XI inhibitor
F11Phase 3Atrial Fibrillation (AF); Venous Thromboembolism (VTE); Peripheral Artery Disease (PAD); End-Stage Kidney Disease (ESKD)Feb 2027
Anthos TherapeuticsAbelacimab (MAA868)
Coagulation factor XI inhibitor
F11Phase 3Atrial Fibrillation (AF)Dec 2027
Suzhou AlphamabKN060
Factor XI inhibitor
F11Phase 2Knee Arthroplasty, Total; Hypertension; End-Stage Renal Disease Requiring HaemodialysisDec 2026
SirnaomicsFXI-GalNAc-siRNA
Factor XI silencing RNA (GalNAc-conjugated siRNA)
F11Phase 1FXIMay 2027

Conditions

Atrial Fibrillation (AF) (7) Venous Thromboembolism (VTE) (4) Peripheral Artery Disease (PAD) (2) End-Stage Kidney Disease (ESKD) (2) Symptomatic Venous Thromboembolism (VTE) (1) Cancer-Associated Thrombosis (CAT) (1) Knee Arthroplasty, Total (1) Hypertension (1) End-Stage Renal Disease Requiring Haemodialysis (1) Ischemic Stroke; Ischemic Attack, Transient (1) Atrial Fibrillation (1) FXI (1)

Modalities

mixed (3), small molecule (2), other (1)

Companies

Regeneron Pharmaceuticals (2) Suzhou Alphamab (1) Anthos Therapeutics (1) Johnson & Johnson (Janssen) (1) Sirnaomics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.